Page 1

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update Quarterly net revenues of $ 133.6 million with 77 % gross margin Last patient enrolled in phase 3 pivotal INNOVATE - 3 trial for recurrent ovarian cancer St. Helier , Jersey - Novocure ( NASDAQ : NVCR ) today reported financial results for the quarter ended September 30 , 2021 , highlighting commercial strength and strategic investment across clinical , product development and commercial initiatives intended to fuel future growth . Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy , Tumor Treating Fields ( TTFields ) . TTFields are electric fields that disrupt cancer cell division . Third quarter 2021 highlights include : Financial , in millions Net revenues Gross Profit Net income ( loss ) Adjusted EBITDA ( 1 ) Non - financial Active patients at period end ( 2 ) Prescriptions received in period ( 3 ) 2021 Three Months Ended September 30 , 2020 % Change 2021 Nine Months Ended September 30 , 2020 % Change $ EA EA EA $ 133.6 $ 132.7 1 % $ 401.8 $ 350.4 $ 103.4 $ 104.3 ( 1 ) % $ 316.6 $ 272.0 15 % 16 % ( 13.1 ) $ 9.3 ( 241 ) % $ ( 31.9 ) $ 14.9 ( 314 ) % $ 19.9 $ 37.3 ( 47 ) % $ 59.2 $ 80.4 ( 26 ) % 3,502 1,380 3,361 4 % 3,502 3,361 4 % 1,371 1 % 4,232 4,202 1 % ( 1 ) Adjusted EBITDA is a non - U.S . GAAP measurement of earnings before interest , taxes , depreciation , amortization and share - based compensation . ( 2 ) An " active patient " is a patient who is receiving treatment under a commercial prescription order as of the measurement date , including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days . ( 3 ) A " prescription received " is a commercial order for Optune or Optune Lua that is received from a physician certified to treat patients for a patient not previously on Optune or Optune Lua . Orders to renew or extend treatment are not included in this total . “ The third quarter was another period of solid execution at Novocure , ” said William Doyle , Novocure's Executive Chairman . " We generated $ 134 million in net revenues and invested $ 48 million across our research , clinical and product development initiatives . We recently completed enrollment in our phase 3 INNOVATE - 3 trial and our phase EF - 31 trial , and announced a new collaboration with global oncology leader ,